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Carotid angioplasty and stenting in anatomically
high-risk patients: Safe and durable except for
radiation-induced stenosis
Susanna H. Shin, MD, Christopher L. Stout, MD, Albert I. Richardson, MD, Richard J. DeMasi, MD,
Rasesh M. Shah, MD, and Jean M. Panneton, MD, Norfolk, Va
Objective: Carotid angioplasty and stenting (CAS) is used in patients considered high-risk for carotid endarterectomy
(CEA). Patients qualify as high-risk because of medical comorbid conditions or for anatomic considerations (previous
CEA, radical neck dissection, radiation). We compared the technical feasibility and durability of CAS in medically
high-risk patients (MED) vs anatomically high-risk patients (ANAT).
Methods: A retrospective review was performed of all consecutive patients undergoing CAS by a single vascular surgery
group. All patients were high risk and evaluated with duplex ultrasound imaging and angiography. Primary end points
were technical success, 30-day stroke, myocardial infarction (MI), death, and in-stent restenosis. Standard statistical
analysis included Kaplan-Meier life tables.
Results: From January 2003 to December 2007, 230 CAS (98 ANAT, 132MED) procedures were attempted. The ANAT
cohort comprised 84 patients with a single anatomic risk factor: 71 with a previous ipsilateral CEA, 6 high lesions, 6
history of neck radiation, and 1 with a tracheostomy. Ten patients had two or three anatomic risk factors: nine with
radical neck dissection and radiation and one with neck radiation and ipsilateral CEA. The mean age was 71.1 years for
ANAT vs 73.9 years for MED (P  .021). Technical success rates were 98% in ANAT and 98.5% in MED (P  .76).
Thirty-day stroke rate was 1.0% in ANAT and 5.3% in MED (P  .14); the mortality rate was 2.0% in ANAT and 0.8%
in MED (P  .79). The 2-year survival free from stroke was MED, 93.6% and ANAT, 98.9% (P  .118); and from
restenosis was MED, 91.9%; and ANAT, 91.0% (P  .98). Two-year overall survival was significantly better in ANAT
(84.6%) vs MED (70.1%; P  .026). Four of the seven restenoses in the ANAT group occurred in patients with previous
neck radiation. The restenosis rate for radiation-induced (RAD) stenosis treated with CAS was significantly higher at
22.2% (4 of 18) compared with 3.8% (3 of 78) in ANAT group patients without a history of radiation (non-RAD; P 
.028). The 2-year restenosis-free survival was 72.7% in the RAD group vs 95.9% in the non-RAD group (P  .017).
Conclusion: CAS is as technically feasible, safe, and durable in anatomically high-risk patients as in medically high-risk
patients, with similar rates of periprocedural stroke and death and late restenosis. However, patients with radiation-
induced stenosis appear to be at an increased risk for restenosis. ( J Vasc Surg 2009;50:762-8.)Carotid endarterectomy (CEA) is the gold standard for
the treatment of carotid artery stenosis in patients with
good operative risk. However, restenosis after CEA and de
novo stenosis in patients with a history of neck irradiation
or radical dissection presents a more difficult treatment
dilemma. CEA in an anatomically complex or scarred neck
increases the risk for adverse local sequelae, including cra-
nial nerve injury, recurrent nerve palsy, cervical hematoma,
and wound dehiscence.1-4 Carotid angioplasty and stenting
(CAS) presents a potential alternative for those patients
deemed too high risk for operative intervention.
CAS has been increasingly performed in patients con-
sidered high risk for CEA since its introduction in the
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762mid-1990s.5-7 Most commonly, the high-risk indication
for CAS is a medical condition making the patient a poor
surgical candidate. Less commonly, CAS is indicated in
anatomically high-risk patients who have a history of neck
irradiation or surgery (radical neck dissection or CEA) or
some other anatomic reason, such as tracheostomy, that
would make CEA particularly hazardous.
The Stenting and Angioplasty with Protection in Pa-
tients at High Risk for Endarterectomy (SAPPHIRE) trial
investigators demonstrated that CAS could be performed
with similar rates of complications as CEA in patients
considered high risk for surgery.8 However, most of the
participants in this trial were medically high-risk patients.
Only a small proportion of the study population was con-
sidered high risk by anatomic considerations, and those
anatomically high-risk patients were not specifically de-
scribed in the trial, making few conclusions possible for the
use of CAS in these patients based on their data.
In this study, we sought to compare the technical
feasibility and the success and durability of CAS in medi-
cally high-risk patients (MED) vs anatomically high risk
patients (ANAT) and identify if there is a subset of patients
at higher risk for restenosis.
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After approval by the Institutional Review Board of
Eastern Virginia Medical School, a retrospective medical
record review was performed of all consecutive patients
who underwent CAS by a single vascular surgery group.
Patients. All patients were considered high risk for
CEA, and operative intervention had been deferred. Crite-
ria for high risk were based on SAPPHIRE criteria8 and
included medical conditions such as clinically significant
cardiac disease, severe chronic obstructive pulmonary dis-
ease, contralateral carotid occlusion, and age 80 years,
and anatomic considerations including previous neck sur-
gery or irradiation therapy to the neck, recurrent stenosis
after CEA, and tracheostomy. Symptomatic patients were
defined as those with a stroke or transient ischemic attack
(TIA) in the distribution of the ipsilateral carotid artery6
months of the procedure. Asymptomatic patients under-
went intervention when internal carotid artery stenosis
80%.
The preprocedural workup included evaluation with
duplex ultrasound (DUS) imaging, with the addition of
computed tomography angiogram (CTA) or diagnostic
carotid angiography, or both, in select patients. Angiogra-
phy was performed before the procedure or at the time of
intervention. Data collected included age, gender, high-
risk criteria, comorbid risk factors, side, procedural data,
preprocedural and follow-up DUS imaging, and clinical
outcomes.
DUS data collected included internal carotid artery
(ICA) and common carotid artery (CCA) peak systolic
(PSV) and end diastolic velocities (EDV) and ICA/CCA
ratios. Standard DUS velocity criteria were used with an
ICA EDV 140 cm/s or an ICA/CCA PSV ratio 4
defining a 80% stenosis.
End points and follow-up. Primary end points in-
cluded technical success, in-stent restenosis 50% at any
point during follow-up, stroke (cerebrovascular accident),
or death at 30 days or at any point during follow-up.
In-stent restenosis was defined as 50% stenosis using
DUS with an ICA PSV220 cm/s and an ICA/CCA PSV
ratio 2.7. We defined an in-stent restenosis 80% by
DUS imaging with an ICA EDV 140 cm/s and an
ICA/CCA PSV ratio 4. Completion carotid DUS imag-
ing was performed 24 hours of CAS in all patients. All
patients were discharged the day after CAS on a clopidogrel
regimen.
Follow-up protocol included a clinical assessment with
DUS imaging at 1 month, 6 to 12 months, then annually
thereafter. CAS was performed in an angiography suite by 1
of 3 vascular surgeons (R. J. D., R. M. S., J. M. P.) alone or
occasionally in conjunction with a vascular surgery fellow or
another vascular surgeon for training or proctoring pur-
poses. Carotid angiography was performed at the start of
each procedure to confirm DUS findings and delineate
anatomy.
Most CAS procedures were performed as part of a
clinical trial (62.6%) or as a postmarketing surveillancestudy, and the type of stent was mandated by the trial. The
number of stents was chosen at the discretion of the sur-
geon. The stents used were all self-expanding, nitinol
stents: Precise or Smart (Cordis, Miami Lakes, Fla), Accu-
link (Guidant, Indianapolis, Ind) or Xact (Abbott, Abbott
Park, Ill). Embolic protection devices (EPDs), including
PercuSurge Guardwire (Medtronic AVE, Santa Rosa,
Calif), Accunet (Guidant Corp), Angioguard (Cordis),
Emboshield (Abbott), and Spider (ev3 Endovascular Inc,
Plymouth, Minn) were used whenever technically feasible.
Statistical analysis.
Data analysis was performed using the t test, Fisher
exact test, 2, Kaplan-Meier life tables, and log-rank test. A
value of P  .05 was used to determine statistical signifi-
cance.
RESULTS
During the 5-year period from January 2003 to De-
cember 2007, 230 CAS (ANAT, 98; MED, 132) were
attempted in 212 patients (ANAT, 94; MED, 118), with
18 patients undergoing bilateral procedures. The ANAT
cohort (mean age, 71.1 years) was significantly younger
than the MED cohort (mean age, 73.9 years; P  .021).
The ANAT cohort consisted of 84 patients with a single
anatomic risk factor: 71 patients with a previous ipsilateral
CEA (2 patients with bilateral ipsilateral CEA), 6 with high
lesions, 6 with a history of neck irradiation, and 1 with a
tracheostomy. Ten patients in the ANAT cohort had more
than one anatomic risk factor: nine had a history of a radical
neck dissection and irradiation, and 1 had neck irradiation,
dissection, and a unilateral CEA with bilateral stenosis. A
total of 18 CAS procedures were performed in 16 patients
who presented with a history of neck irradiation.
The ANAT and MED cohorts were similar in gender
distribution and proportion of patients aged 80 years.
The two groups were also similar in rates of several cardio-
vascular risk factors, including hypertension, hyperlipid-
emia, current tobacco use, and a history of stroke, chronic
obstructive pulmonary disease, and congestive heart failure
(Table I). The MED cohort had a significantly higher
number of patients with symptomatic ipsilateral stenosis,
diabetes mellitus, end-stage renal disease, coronary artery
disease, and contralateral carotid artery occlusion.
Outcomes. Technical success was achieved in 96 of 98
ANAT patients (98.0%) and in 130 of 132 MED patients
(98.5%; P .76). In the MED cohort, CAS was aborted in
a patient with a tortuous ICA that could not be crossed
safely and in another patient with a highly calcified ICA that
could not be cannulated. In the ANAT cohort, one case
was aborted because the ICA branched off the CCA at a
right angle, which required a significant amount of manip-
ulation, and it was determined to be unsafe to continue. A
second aborted case in the ANAT cohort involved a tortu-
ous ICA restenosis after CEAwith an excessively redundant
artery.
An EPD was used in 129 of 130 patients in the MED
cohort (99.2%) compared with 89 of 96 in the ANAT
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CAS procedures (MED, 122; ANAT, 89), with the remain-
ing procedures requiring two stents (MED, 8; ANAT, 7;
P  .79). Two of these procedures requiring two stents
were in patients with a history of previous neck irradiation.
Mean follow-up was 21.5 months in the ANAT group
compared with 10.5 months inMED patients (P .0001).
The number of strokes at 30 days was not significantly
different between the two cohorts (ANAT, 1 of 98 [1.0%],
MED, 7 of 132 [5.3%], P .14). Of the eight strokes that
occurred, seven were in patients who were symptomatic at
the time of CAS (MED, 6 of 7; ANAT 1 of 1). In the
medically high-risk cohort, strokes occurred in 9.7% of the
symptomatic patients (6 of 62) and in only 1.4% of the as-
ymptomatic patients (1 of 70; P  .051). The stroke-free
survival, using Kaplan-Meier method, was not statistically
different between the two cohorts at 1 year (MED, 93.6%;
ANAT, 98.9%) or at 2 years (MED, 93.6%; ANAT, 98.9%;
P  .118; Fig 1).
The 30-day mortality rate was similar and low between
the two cohorts, at 2.0% for and 0.8% for MED (P  .79;
Table II). The 30-day combined event rate of stroke and
death was 2.0% for ANAT and 5.3% for MED (P  .31).
Overall survival after CAS was significantly better in the
ANAT group than the MED group at 1 year (ANAT,
89.5%, MED, 85.1%) and at 2 years (ANAT, 84.6%, MED,
70.1%; P  .026; Fig 2).
During follow-up, there were 12 cases of restenosis,
seven in the ANAT cohort (7.3%) and five in the MED
cohort (3.8%; P  .36). There was no statistical difference
in the survival free of restenosis between the two groups at
1 year (MED, 91.9%; ANAT, 95.2%) or at 2 years (MED,
91.9%; ANAT, 91.0%; P  .98; Fig 3).
Radiation-induced stenosis. Four of the seven cases
of restenosis in the ANAT group occurred in patients with
previous neck irradiation (Table III). Three of those pa-
Table I. Patient characteristics
Characteristic
MED ANAT
P(n  118) (n  94)
Age, mean  SD, y 73.9  0.8 71.1  1.0 .021
Male gender (%) 62.9 52 .1065
Follow-up, mean  SD, y 10.5  0.9 21.5  1.9 .0001
Symptomatic, % 47.0 31.6 .0213
Age 80 y, % 30.3 23.5 .296
Hypertension, % 93.9 90.8 .4475
Hyperlipidemia, % 89.4 84.7 .3192
Diabetes mellitus, % 40.9 24.5 .0112
End-stage renal disease, % 8.3 1 .0149
Coronary artery disease, % 75 56.1 .003
Current tobacco use, % 47 59.2 .0827
Prior stroke, % 29.5 32.7 .6659
Congestive heart failure, % 0.8 0 .99
Contralateral carotid
occlusion, %
20.5 5.1 .0009
ANAT, Anatomically high-risk cohort; MED, medically high-risk cohort;
SD, standard deviation.tients underwent reintervention. Restenosis developed at9.1 and 58.8 months in two patients with a history of
radiotherapy and radical neck dissection. The restenosis in
the first patient was treated with cutting balloon angio-
plasty and an EPD, leaving 10% residual stenosis. The
Fig 1. Kaplan-Meier stroke-free survival curves for the medical
high-risk (MED) cohort (black line) and anatomic high-risk (ANAT)
cohort (gray line)were similar at 1 year (MED,93.6%;ANAT,98.9%)
and 2 years (MED, 93.6%; ANAT, 98.9%; P  .118). Abbreviated
life-table data are included along the horizontal axis.
Table II. Outcomes at 30 days
Outcome
MED ANAT
P(n  132) (n  98)
Rate at 30-days, No. (%)
Stroke 7 (5.3) 1 (1.0) .14
Mortality 1 (0.8) 2 (2.0) .79
Stroke and mortality 7 (5.3) 2 (2.0) .31
ANAT, Anatomically high-risk cohort; MED, medically high-risk cohort.
Fig 2. Kaplan-Meier overall survival curves were better for the ana-
tomic high-risk (ANAT) cohort (gray line) than for the medical
high-risk (MED) cohort (black line) at 1 year (ANAT, 89.5%; MED,
85.1%) and 2 years (ANAT, 84.6%; MED, 70.1%; P .026). Abbre-
viated life-table data are included along the horizontal axis.second patient underwent redo CAS with similar results. In
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The patient underwent redo CAS and the outcome was
favorable, with no residual stenosis.
The restenosis rate for radiation-induced stenosis
(RAD) treated with CAS was significantly higher at 22.2%
(4 of 18) compared with 3.8% (3 of 78; P  .028) for all
other CAS performed in the ANAT group (non-RAD).
The restenosis-free survival at 1 year (RAD, 83.1%; non-
RAD, 98.3%) and at 2 years (RAD, 72.7%; non-RAD,
95.9%; P  .017; Fig 4) was significantly better in those
ANAT patients who had no history of neck irradiation.
DISCUSSION
CAS is increasingly being performed for ICA stenosis in
patients who are high risk for CEA for anatomic reasons.
Previous neck surgery (ipsilateral CEA and radical neck
dissection) and radiotherapy are the most common reasons
CAS is chosen rather than CEA. For a surgeon, these
indications for CAS are amongst the most desirable intu-
Fig 3. Kaplan-Meier curves show restenosis-free survival for the
medical high-risk (MED) cohort (black line) and anatomic high-
risk (ANAT) cohort (gray line) were similar at 1 year (MED,
91.9%; ANAT, 95.2%) and 2 years (MED, 91.9%; ANAT, 91.0%;
P  .98). Abbreviated life-table data are included along the hori-
zontal axis.
Table III. Restenosis in the anatomically high-risk
cohort
Patient
High-risk
criteria
Patency, mon
ReinterventionPrimary
Assisted
primary
1 XRT, RND 7.5 7.5 None
2 CEA 9.9 9.9 None
3 XRT, RND 9.1 12.8 Angioplasty
4 XRT, CEA 13.4 14.1 CAS
5 CEA 16.6 16.6 None
6 CEA 25.4 25.4 None
7 XRT, RND 58.8 59.3 CAS
CAS, Carotid angioplasty and stenting; CEA, ipsilateral carotid endarterec-
tomy; RND, radical neck dissection; XRT, neck irradiation.itively because of the difficulties encountered in a reopera-tive or irradiated neck. The “hostile neck” from a history of
a neck dissection or radiotherapy places the patient at a
higher risk for local complications and restenosis. These are
the patients who would appear to benefit the most surgi-
cally by remaining outside of the area of most concern. This
is in contrast to those patients who are at a higher risk
medically for cardiac events from the anesthesia and other
complications and death.
Contralateral occlusion has not been shown to increase
the risk associated with CEA in multiple studies.9,10 How-
ever, we believe that it is, rather, an indicator of carotid
disease and increases the patient’s medical risk for compli-
cations. For these reasons, although contralateral carotid
occlusion is traditionally included in the anatomically high-
risk cohort, we believed these patients fit more appropri-
ately in the medical high-risk cohort. However, although
these situations are not rare, they are certainly not com-
mon, and lesion-specific CAS outcome data have been
lacking. In our study, 98 patients with anatomically difficult
necks underwent attempted CAS with similar technical
success, safety, and durability as in the medically high-risk
group.
Treating radiation-induced arteritis has been challeng-
ing in the past, with a high rate of complications with CEA.
CEA in a cervical field that has undergone an operation or
has been irradiated has historically increased the risk of local
complications compared with primary CEA in a nonirradi-
ated cervical field.1,3,4,11-15 Previously, the rates of cranial
nerve injury, hematoma, and restenosis have been increased
in this population, although the data is somewhat con-
flicted.
The North American Symptomatic Carotid Endarter-
Fig 4. Kaplan-Meier curves show restenosis-free survival was sig-
nificantly better for the patients in the anatomic high risk cohort
without a history of radiation (non-RAD, gray line) than for those
patients in the anatomic high risk cohort with a history of radiation
(RAD, black line) at 1 year (non-RAD, 98.3%; RAD, 83.1%) and 2
years (non-RAD, 95.9%; RAD, 72.7%; P  .017). Restenosis-free
survival for patients without a history of radiation at 3 years was
92.8%. The standard error of the mean was 10% past 2 years
(dotted line). Abbreviated life-table data are included along the
horizontal axis.ectomy Trial (NASCET) investigators demonstrated an
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cation rate in primary CEAs.16 In comparison, in 1993
Gagne et al1 published their series of 47 redo carotid artery
reconstructions with a 4.3% cranial nerve injury rate. Simi-
larly, in 1997 Mansour et al4 demonstrated a 7.3% cranial
nerve injury rate and a 2.4% wound hematoma rate.4 These
are in contrast to the series published by AbuRahma et al3
in 2001, where the cranial nerve injury was 17% in their
redo CEA compared with 5.3% in the primary CEAs.3 With
this increased risk of local complications with CEA in an
anatomically high-risk patient, CAS was postulated to pro-
vide a suitable, less risky alternative to CEA.
Early attempts at CAS in radiation-induced stenosis
were largely unsuccessful. Melliere et al17 attempted CAS
in a single patient with radiation-induced stenosis. The
procedure was aborted because the patient lost conscious-
ness when the balloon was inflated.17 Teitelbaum et al18
reported their series of CAS in high-risk patients with one
case of radiation-induced stenosis. Initially, this was tech-
nically successful but was occluded 6 months. Cheng et
al19 performed four CAS procedures in radiation-induced
stenosis and achieved technical success, but one postoper-
ative stroke occurred after stent migration that thrombosed
and later led to a fatal cerebral hemorrhage.
As time has passed, experience with CAS has improved
and yielded better results. In 2007 Eskandari et al20 pub-
lished a series of 269 CAS with 66 successful procedures in
hostile necks, which included patients with previous CEA
or irradiation. At 30 days, the stroke rate was 2.2% (1.1%
minor stroke rate and 1.1% major stroke rate), and the
myocardial death rate was 0.4%; however, none of these
adverse events occurred in the hostile neck group.
EPDs have been proven to be safe and shown to
decrease neurologic events.21-23 CAS should be performed
routinely with an EPD. This was the goal in all of our
patients, but EPDs were used significantly less in our
ANAT cohort. Most of these patients who did not have an
EPD were early in our experience with CAS (2003), when
few options were available for their use. Almost all of these
patients were in the anatomically high-risk cohort, so the
rate of EPD usage was significantly lower. Therefore, it was
not a failure to deploy the EPD, but that EPDs were not
used routinely in our early experience. Later, when studies
demonstrated the benefits of EPDs, their use became rou-
tine.
Interestingly, the less frequent use of EPD in the ana-
tomically high-risk cohort was not associated with an in-
creased periprocedural stroke rate. In fact, the stroke rate in
the hostile neck group was low, with only one stroke
occurring in the 30 days after CAS. The 30-day stroke rate
in the medically high-risk group was 5.3%, however, which
was higher than expected considering more than half the
patients were asymptomatic at the time of CAS. In the
medically high-risk group, 85.7% of the strokes were in
symptomatic patients. The stroke rate was lower in the
anatomically high-risk group, although this difference was
not statistically significant. A significantly greater propor-
tion of the anatomically high-risk cohort was asymptom-atic, however, and this may explain the lower incidence of
strokes.
In this series, CAS was attempted in 98 high-risk pa-
tients with carotid artery stenosis considered high risk for
CEA for anatomic reasons. This included 18 patients with
radiation-induced arteritis, for which CAS was 100% tech-
nically successful.
A recent study by Eskandari et al20 demonstrated an
overall restenosis or occlusion rate of 2.6%, which was
statistically the same between the hostile neck and the de
novo lesions (4.5% vs 2.0%). This is not a completely
comparable group, however, because the hostile neck
group included 40 patients with restenosis after CEA and
26 with radiation-induced arteritis. The authors were able
to successfully treat all restenosis with repeat CAS in some
cases, with no periprocedural stroke, death, or restenosis.
Protack et al,24 published a similar series to ours with
fewer patients overall (N  150), but a greater proportion
of their patients had radiation-induced stenosis (n  23).
Asymptomatic occlusions only occurred in the radiation
group, and the restenosis-free survival at 3 years was signif-
icantly worse in the radiation group (20%) compared with
all other patients undergoing CAS (74%).
Radiation-induced arteritis is considered one of the
strongest and most appealing indications for CAS, making
these poor long-term results for CAS in these patients
troublesome. CAS was successful initially in our patients,
but during the long-term follow-up, the restenosis rate in
this subgroup was significantly higher. Our ANAT cohort
had longer follow-up. In our practice, patients with a
hostile neck were amongst the first to be offered CAS. CAS
was not performed inmedically high-risk patients until later
within the trials. This is likely the explanation for the longer
follow-up in the anatomically high-risk patients.
Our experience and the series published by Protack et
al24 prompts the question of whether radiation-induced
arteritis should not be treated with CAS. Despite advances
and improvement in the stents used in CAS, the results with
radiation-induced arteritis continue to be disappointing.
This study has described the clinical question of CAS in
radiation-induced arteritis but is limited by the retrospec-
tive design and the small numbers due to the rarity of the
condition. The small numbers of the study may contribute
to the lack of a significant difference in the 30-day stroke
rate between the medically and anatomically high-risk co-
horts. Our data show a trend toward more strokes in the
medically high-risk cohort, but the value of P does not
reach statistical significance and may be due to the lack of
power. With a larger sample size it is possible that this may
or may not reach statistical significance.
Future possible options for the treatment of radiation-
induced arteritis will include covered or drug-eluting stents
to improve long-term patency in these difficult patients.
However, although CAS for radiation-induced arteritis
does have a higher rate of restenosis, we still believe it is a
better therapeutic option for these patients than CEA.
Currently, we continue to use CAS in these patients and
until a better option is found, we will continue to do so.
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CAS is as technically feasible, safe, and durable in
anatomically high-risk patients as in medically high-risk
patients, with similar rates of periprocedural stroke, death,
and late restenosis. However, patients with radiation-
induced stenosis appear to be at an increased risk for res-
tenosis.
AUTHOR CONTRIBUTIONS
Conception and design: SS, JP, AR
Analysis and interpretation: SS, JP
Data collection: SS, AR, CS
Writing the article: SS, JP
Critical revision of the article: SS, JP
Final approval of the article: SS, JP
Statistical analysis: SS, CS
Obtained funding: JP, RD, RS
Overall responsibility: JP
REFERENCES
1. Gagne PJ, Riles TS, Jacobowitz GR, Lamparello PJ, Giangola G,
Adelman MA, et al. Long-term follow-up of patients undergoing reop-
eration for recurrent carotid artery disease. J Vasc Surg 1993;18:991-8;
discussion 999-1001.
2. Hassen-Khodja R, Sala F, Declemy S, Lagrange JL, Bouillane PJ, Batt
M. Surgical management of atherosclerotic carotid artery stenosis after
cervical radiation therapy. Ann Vasc Surg 2000;14:608-11.
3. AbuRahma AF, Jennings TG, Wulu JT, Tarakji L, Robinson PA. Redo
carotid endarterectomy versus primary carotid endarterectomy. Stroke
2001;32:2787-92.
4. Mansour MA, Kang SS, Baker WH, Watson WC, Littooy FN, Labro-
poulos N, et al. Carotid endarterectomy for recurrent stenosis. J Vasc
Surg 1997;25:877-83.
5. Diethrich EB, Ndiaye M, Reid DB. Stenting in the carotid artery: initial
experience in 110 patients. J Endovasc Surg 1996;3:42-62.
6. Yadav JS, Roubin GS, Iyer S, Vitek J, King P, Jordan WD, et al. Elec-
tive stenting of the extracranial carotid arteries. Circulation 1997;95:
376-81.
7. Bergeron P, Becquemin JP, Jausseran JM, Biasi G, Cardon JM, Castel-
lani L, et al. Percutaneous stenting of the internal carotid artery: the
European CAST I study. Carotid artery stent trial. J Endovasc Surg
1999;6:155-9.
8. Yadav JS, Wholey MH, Kuntz RE, Fayad P, Katzen BT, Mishkel GJ,
et al. Protected carotid-artery stenting versus endarterectomy in high-
risk patients. N Engl J Med 2004;351:1493-501.
9. Fitzpatrick CM, Chiou AC, DeCaprio JD, Kashyap VS. Carotid revas-
cularization in the presence of contralateral carotid artery occlusion is
safe and durable. Mil Med 2005;170:1069-74.
higher risks of restenosis in patients with radiation-induced carotid10. Domenig C, Hamdan AD, Belfield AK, Campbell DR, Skillman JJ,
LoGerfo FW, et al. Recurrent stenosis and contralateral occlusion:
high-risk situations in carotid endarterectomy? Ann Vasc Surg 2003;17:
622-8.
11. AbuRahma AF, Snodgrass KR, Robinson PA, Wood DJ, Meek RB,
Patton DJ. Safety and durability of redo carotid endarterectomy for
recurrent carotid artery stenosis. Am J Surg 1994;168:175-8.
12. Elerding SC, Fernandez RN, Grotta JC, Lindberg RD, Causay LC,
McMurtrey MJ. Carotid artery disease following external cervical irra-
diation. Ann Surg 1981;194:609-15.
13. Moritz MW, Higgins RF, Jacobs JR. Duplex imaging and incidence of
carotid radiation injury after high-dose radiotherapy for tumors of the
head and neck. Arch Surg 1990;125:1181-3.
14. Atkinson JL, Sundt TM Jr, Dale AJ, Cascino TL, Nichols DA.
Radiation-associated atheromatous disease of the cervical carotid artery:
report of seven cases and review of the literature. Neurosurgery 1989;
24:171-8.
15. Kashyap VS, Moore WS, Quinones-Baldrich WJ. Carotid artery repair
for radiation-associated atherosclerosis is a safe and durable procedure.
J Vasc Surg 1999;29:90-6; discussion 97-9.
16. Ferguson GG, Eliasziw M, Barr HW, Clagett GP, Barnes RW, Wallace
MC, et al. The North American Symptomatic Carotid Endarterectomy
Trial: surgical results in 1415 patients. Stroke 1999;30:1751-8.
17. Melliere D, Becquemin JP, Berrahal D, Desgranges P, Cavillon A.
Management of radiation-induced occlusive arterial disease: a reassess-
ment. J Cardiovasc Surg (Torino) 1997;38:261-9.
18. Teitelbaum GP, Lefkowitz MA, Giannotta SL. Carotid angioplasty and
stenting in high-risk patients. Surg Neurol 1998;50:300-11; discussion
311-2.
19. Cheng SW, Wu LL, Ting AC, Lau H, Lam LK, Wei WI. Irradiation-
induced extracranial carotid stenosis in patients with head and neck
malignancies. Am J Surg 1999;178:323-8.
20. Eskandari MK, Brown KE, Kibbe MR, Morasch MD, Matsumura JS,
Pearce WH. Restenosis after carotid stent placement in patients with
previous neck irradiation or endarterectomy. J Vasc Interv Radiol
2007;18:1368-74.
21. Zahn R, Mark B, Niedermaier N, Zeymer U, Limbourg P, Ischinger T,
et al. Embolic protection devices for carotid artery stenting: better
results than stenting without protection? Eur Heart J 2004;25:1550-8.
22. Grube E, Gerckens U, Yeung AC, Rowold S, Kirchhof N, Sedgewick J,
et al. Prevention of distal embolization during coronary angioplasty in
saphenous vein grafts and native vessels using porous filter protection.
Circulation 2001;104:2436-41.
23. Terada T, Yamaga H, Tsumoto T, Masuo O, Itakura T. Use of an
embolic protection system during endovascular recanalization of a
totally occluded cervical internal carotid artery at the chronic stage. Case
report. J Neurosurg 2005;102:558-64.
24. Protack CD, Bakken AM, Saad WE, Illig KA, Waldman DL, Davies
MG. Radiation arteritis: a contraindication to carotid stenting? J Vasc
Surg 2007;45:110-7.Submitted Feb 22, 2009; accepted Apr 24, 2009.DISCUSSION
Dr Peter Lin (Houston, Tex). Dr Shin and her colleagues from
the Eastern Virginia Medical School should be congratulated for
an excellent clinical study in which they analyzed the clinical
outcome of carotid stenting in patients who have high-risk medical
comorbidities vs those with anatomically high-risk lesions. The
authors reported similar clinical outcome in terms of stroke and
mortality between the two groups. However, patients with
radiation-induced stenosis had a much higher risk of restenosis
compared to the medically high-risk cohorts. I have three ques-
tions for the author.
My first question relates to the ultrasound surveillance. Thelesions, inmy view, warrants a more vigilant or frequent ultrasound
surveillance protocol since the need for reintervention is undoubt-
edly higher. Can you share with us your view whether a more
vigilant surveillance protocol is necessary in this particular patient
cohort? If so, what should be the ideal surveillance protocol in
these patients?
Second, in your study, a variety of carotid stents including the
Smart, Precise, and Acculink stents were used. There have been
studies in the recent literature to suggest these nitinol stents, which
are considered a open-cell stent, have lower patency compared to
closed-cell stents such as Wallstent. This is a finding that we have
also validated in our own clinical experience. This finding has also
